Dec 20 (Reuters) - Kalytera Therapeutics Inc KALY.V :
* KALYTERA PROVIDES UPDATE ON PHASE 2 CLINICAL STUDY EVALUATING CBD IN PREVENTION OF ACUTE GVHD
* KALYTERA THERAPEUTICS INC - CBD DEMONSTRATED A GOOD SAFETY & TOLERABILITY PROFILE, WITH NO SIGNIFICANT ADVERSE EVENTS RELATING TO ITS USE
* KALYTERA THERAPEUTICS INC - PLANNED PHASE 3 STUDY EXPECTED TO INITIATE IN 2019
* KALYTERA THERAPEUTICS INC - U.S. FDA HAS RECOMMENDED THAT CO APPLY FOR BOTH BREAKTHROUGH THERAPY AND FAST TRACK DESIGNATIONS FOR ITS CBD PRODUCTS